Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of AZD0530 in Hormone Refractory Prostate Cancer (HRPC)

NCT00513071 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00513071
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00513071 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of AZD0530 in Hormone Refractory Prostate Cancer (HRPC)
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2007
Completion date
October 31, 2008
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hormone-resistant prostate cancer, recurrent prostate cancer